This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Their Use in Acute Severe Dermatological Conditions

ROBERT H. PRESTON, M.D.; RICHARD FLATT, M.D.

AMA Arch Derm. 1956;74(6):613-614.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Intravenous corticotropin has been of value in the immediate treatment of acute and severe dermatological conditions. The chief disadvantage was the drip technique and consequent hospitalization of the patient.^* Intravenous hydrocortisone was next used by us, especially for acute lupus erythematosus in crisis and in Waterhouse-Friderichsen syndrome. This corticosteroid in alcohol also required a slow intravenous drip.

With the development of the new soluble hemisuccinate compounds of hydrocortisone and its analogue, prednisolone, attention was again directed to the use of these for the rapid and intensive therapy of acute and severe dermatological conditions. Moreover, the small volume of prepared solutions, 1-2 cc., allowed the use of this in ambulatory patients, and hospitalization was not necessary.

A group of 10 cases were so studied. The dosage varied. The hydrocortisone hemisuccinate varied from 50 mg. twice a day to 50 mg. three times a day. Several cases were . . . [Full Text PDF of this Article]

Author Affiliations
Cincinnati

From The Department of Dermatology of the College of Medicine of The University of Cincinnati. Hydrocortisone hemisuccinate and prednisolone hemisuccinate furnished by The Upjohn Company and by Merck and Company, Inc.

Footnotes
Submitted for publication March 5, 1956.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?